

From: Bowen, Kevin [mailto:k.bowen@okstate.edu]
Sent: Tuesday, January 16, 2007 12:54 PM
To: Scudiero, Janet L.
Cc: Bowen, Kevin
Subject:

Kevin J. Bowen
P.O. Box 905
Atoka, OK 74525
(580) 889-5151

To

janet.scudiero@fda.hhs.gov.

Thank-you for contacting us with availability of a new type of therapy for people with depression disorders.

I hope and recommend that the FDA will convene the Neurological Devices Panel, a group of non-FDA experts in Neurology and Psychiatry, on January 26th to review the efficacy and safety of NeuroStar TMS Therapy and approve the system for use.

I, a long time patient of schizophrenia would appreciate being in a controlled trial where rTMS has been used largely to target treatment-refractory hallucinations. Repetitive TMS is generally applied at 1Hz frequency over the left temporoparietal cortex with the intent of inhibiting dysfunctional auditory processing pathways in Wernicke's area that in turn may be linked to the production of auditory hallucinations. If further studies are needed to clarify the role of rTMS in this application please contact me.

Sincerely,

Kevin Bowen